Medical Doctor Shares Life Changing Ibogaine Treatment Stories

Dr. Fernando Vega, a family physician with 45 years of practice, has become a leading figure in psychedelic therapy just as the U.S. government, under President Trump, signaled a shift toward expanding research on psychedelics for PTSD and veteran care. Vega’s clinic in Seattle blends conventional medicine with alternative approaches, offering MDMA, psilocybin, 5‑MeO‑DMT, and especially ibogaine. His extensive experience—over 600 patients treated—places him at the forefront of a movement that could reshape how chronic mental health and addiction are addressed, providing a real‑world counterpoint to academic studies.

Ibogaine, derived from an African plant, is highlighted for its ability to interrupt opioid and alcohol dependence almost instantly. Vega recounts a former alcoholic who, after a coma, regained speech, motor control, and sobriety following a single ibogaine session, even reclaiming his driver’s license. To protect his work, Vega video‑recorded every treatment, amassing hundreds of hours of clinical footage that serve as rare, systematic documentation in an otherwise underground field. This rigorous record‑keeping, however, attracted scrutiny; the medical board ultimately suspended his license after discovering the unregistered psychedelic protocols, underscoring the regulatory tension between innovative care and established medical oversight.

The conversation also reveals a growing collaboration between Western clinicians and traditional Bwiti shamans, who administer ibogaine either as purified HCl or as raw wood. While HCl offers predictable dosing, the wood retains cultural and energetic nuances valued by practitioners. Vega’s network spans veterans in Texas, opioid users in Mexico, and Native American communities, illustrating the global demand for plant‑based therapies. As policy evolves and more clinical trials emerge, the blend of scientific rigor, video documentation, and cross‑cultural partnership may pave the way for broader acceptance of ibogaine and other psychedelics in mainstream medicine.